# Process for the preparation of beta lactam compounds and intermediates therefor.

## Abstract
A process for preparing a compound of partial structure The compound of partial structure I can be converted in situ to a compound of partial structure

## Claims
CLAIMS 1. A process for the preparatiotl of an imine having the partial structure I EMI31.1 wherein R1 is a carboxylic acyl group, which process comprises trotting a ss lactam having the partial structure II EMI31.2 wherein R2 is a halogen atom with a non nucleophilic base. 2. A process for the preparation of a compound of formula III or a salt thereof EMI31.3 wherein R1 is a carboxylic acyl group, Rx is hydrogen or a readily removable carboxyl protecting group and Y is EMI32.1 wherein Y is sulphur, SO or S02, yl is oxygen, sulphur, SO, S02 or CH2 and Z represents hydrogen, halogen, or an organic group such as C14 alkoxy, CH2Q or CH CH Q wherein Q represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carbamoyloxy, carboxylic ester, C14 alkyloxy, acyloxy, aryl, a heterocyclyl group bonded via carbon, a heterocyclylthio group or a nitrogen containing heterocyclic group bonded via nitrogen, which process comprises treating an intermediate of formula IV EMI32.2 wherein R2 is a halogen atom and R1, Rx and Y are as hereinbefore defined with a non nucleophilic base. 3. A process as claimed in claim 2 wherein R1 is benzyloxycarbonyl optionally substituted in the phenyl ring by one or two substituents selected from C14 alkyl, C14 alkoxy, trifluoromethyl, halogen or nitro, or wherein R1 is C14 alkyloxycarbonyl optionally substituted in the alkyl group by up to three substituents chosen from C1 4 alkoxy, halo or nitro. 4. A process as claimed in Claim 2 or Claim 3 in which R1 is 2,2,2 trichloroethoxycarbonyl, ethoxycarbonyl, benzyloxycarbonyl or 4 nitrobenzyloxycarbonyl. 5. A process as claimed in any one of Claims 2 to 4 wherein R2 is chlorine. 6. A process as claimed in any one of Claims 2 to 5 wherein the non nucleophilic base is l 1,8 iazabicyclo 5.4.0 undec 7 ene. 7. A process as claimed in any one of Claims 2 to 6 wherein Y is EMI33.1 8. A process for the preparation of a compound having the partial structure VI EMI34.1 wherein R1 is a carboxylic acyl group, which process comprises preparing an imine having the partial structure I by a process as claimed in Claim 1 and adding in situ a nucleophilic derivative of formamide. 9. A process for the preparation of a compound of formula VII or a salt thereof EMI34.2 wherein any reactive groups may be protected R1 is a carboxylic acyl group, R3 is hydrogen or a readily removable carboxyl proteting group and Y is as defined with respect to formula III , which process comprises preparing an imine of formula III by a process as claimed in any one of Claims 2 to 7 and adding in situ a nucleophilic derivative of formamide and thereafter, if necessary, carrying out one or more of the following steps i removing any protecting groups ii converting a group Rx to a group R3 iii converting one group Z into a different group Z iv converting the product into a salt. 10. A process as claimed in Claim 9 wherein the nucleophilic derivative of formamide is N,N bis tri loweralkylsilyl fonnarnide. 11. A process as claimed in Claim 9 or Claim 10 wherein the nucleophilic derivative of formamide is ,N bis trimethylsilylformamide. 12. A process for the preparation of a compound of formula X or a salt thereof EMI35.1 wherein R3 is hydrogen or a readily removable carboxy protecting group and Y is as defined with respect to formula III , which process comprises preparing a compound of formula VII by the process as claimed in any one of Claims 9 to 11, thereafter removing to amino protecting group R1 and finally, if necessary, carrying out one or more of the following steps i removing any further protecting groups ii converting a group Rx into a group R3 iii converting one group Z into a different group Z iv converting the product into a salt.

## Description
CHEMICAL PROCESSThis invention relates to a chemical process for the preparation of lactam compounds and intermediates therefor, which process is particularly useful when a formamido substituent is to be introduced into a lactam at the carbon atom adjacent to the carbonyl group in the lactam ring. Certain of the substituted lactam compounds produced by the process are antibacterial agents others are useful as intermediates for producing such agents. Each of these groups is described below.The present invention provides a process for the preparation of an imine having the partial structure I EMI1.1 wherein R1 is a carboxylic acyl group, which process comprises treating a compound having the partial structure II EMI1.2 wherein R2 is a halogen atom, with a non nucleophilic base.By carboxylic acyl group herein is meant an aryloxycarbonyl, arylalkyloxycarbonyl, or alkoxycarbonyl group of the formula R O CO wherein R is aryl, aryl C16 alkyl or optionally substituted C1 6 alkyl It will therefore be appreciated that the compounds of formula II areN halocarbamates N halourethanes .Suitably the group R1 is a removable amino protecting group of the urethane type which may if desired be removed from a compound of formula I or, more suitably, from a product for which the compound of formula I serves as an intermediate. Examples of suitable protecting groups of this nature, and conditions for their removal without disruption of the remainder of the molecule are well known in the art.Suitable removable amino protecting carboxylic acyl groups for R1 include benzyloxycarbonyl optionally substituted in the phenyl ring by one or two substituents selected from C14 alkyl, C14 alkoxy, trifluoromethyl, halogen or nitro C14 alkyloxycarbonyl, for example tert butoxycarbonyl or C1 4 alkyloxycarbonyl optionally substituted in the alkyl group by up to three substituents chosen from C14 alkoxy, halo or nitro, for example 2,2,2,trichloroethoxycarbonyl or l chloroethoxycarbonyl. Preferred examples of removable amino protecting acyl groups within R1 include those listed above which are removable under acid conditions optionally in the presence of a group IIb metal.Particular carboxylic acyl groups for R1 include 2,2,2 trichloroethoxycarbonyl, ethoxycarbonyl and benzyloxycarbonyl, and 4 nitrobenzyloxycarbonyl.The term halogen refers to fluorine, chlorine, bromine and iodine.A preferred halogen atom for R2 is chlorine.Suitable non nucleophilic bases for use in the process include 1,8 diazabicyclo ES.4.0 undec 7 ene, 1,5diazabicyclo 4.3.0 non 5 ene, 1,4 diazabicyclo E2.2.2 octane, dimethylaminopyridine or a tri lower alkyl amine.A preferred base is 1,8 diazabicyclo 5.4.0 undec 7 ene DBU .Suitable solvents in which the reaction may be performed include for example, tetrahydrofuran, dimethylformamide, dichloromethane and methylisobutylketone. The reactions are generally carried out under an inert atmosphere and at moderate to low temperature ie in the range 100 C to 300C. A suitable example of a compound of partial structure I is a compound of formula III EMI4.1 wherein R1 is as defined hereinbefore Rx is hydrogen or a readily removable carboxyl protecting group and Y is EMI4.2 wherein Y0 is sulphur, SO or S02, yl is oxygen, sulphur, SO, S02 or CH2 and Z represents hydrogen, halogen, or an organic group such as C14 alkoxy, CH2Q or CH CH Q wherein Q represents hydrogen, halogen, hydroxy, mercapto, cyano, carboxy, carbamoyloxy, carboxylic ester, C14 alkyloxy, acyloxy, aryl, a heterocyclyl group bonded via carbon, a heterocyclylthio group or a nitrogen containing heterocyclic group bonded via a nitrogen atom.Suitable values for Q in the compounds of the formula III include the acetoxy, heterocyclylthio group, and nitrogen containing heterocyclic group bonded via nitrogen. More suitably Q represents the acetoxy or heterocyclylthio group.The heterocyclylthio group may suitably be represented by the formula S Het wherein Het is a five or six membered heterocyclic ring containing from 1 to 4 atoms selected from N, O, and S unsubstituted or substituted with one or two groups selected from C16 alkyl, C1 6 alkoxy, hydroxyalkyl, C1 6 alkenyl, alkoxyalkyl, carboxyalkyl, sulphonylalkyl, carbamoylalkyl, trifluoromethyl, hydroxy, halogen, oxo, optionally substituted aminoalkyl, and carboxyalkyl or two substituents may be linked to form the residue of a heterocyclic or carbocyclic ring.Examples of the group Het include unsubstituted and substituted imidazolyl, triazolyl, tetrazolyl, thiazolyl, thiadiazolyl, thiatriazolyl, oxazolyl, triazinyl and oxadiazolyl.Suitable groups Het include unsubstituted and substituted 1, 2, 3 triazolyl 1, 2, 4 triazolyl tetrazolyl oxazolyl thiazolyl 1, 3, 4 oxadiazolyl 1, 3, 4 thiadiazolyl or 1, 2, 4 thiadiazolyl.Preferably the heterocyclylthio group is l methyl lH tetrazol 5 ylthio, 2 methyl 1,3,4 thiadiazol 5 ylthio, l carboxymethyl lH tetrazol 5 ylthio or 6 hydroxy 2 methyl 5 oxo 2H 1,2,4 triazin 3 ylthio. The nitrogen containing heterocyclic group bonded via nitrogen is suitably a pyridinium group unsubstituted or substituted with one or two groups selected from C16 alkyl, C16 alkoxy, hydroxyalkyl, C16 alkenyl, alkoxyalkyl, carboxyalkyl, sulphonylalkyl, carbamoylmethyl, carbamoyl, trifluoromethyl, hydroxy, halogen, oxo, aminoalkyl, or two substituents on adjacent carbon atoms may form the residue of a carbocyclic ring.When used herein the term carboxylic ester unless otherwise defined suitably includes C1 6 alkyl esters.When used herein the term acyloxy unless otherwise defined suitably includes C16 alkylcarbonyloxy groups.When used herein the term aryl unless otherwise defined suitably includes phenyl and naphthyl, preferably phenyl, optionally substituted with up to five halogen, C16 alkyl, C16 alkoxy, halo C1 6 alkyl, hydroxy, amino, carboxy, C16 alkoxycarbonyl, or C16 alkoxycarbonyl C1 6 alkyl, C16 alkylcarbonyloxy or C16 alkoxycarbonyloxy groups. When used herein the term heterocyclyl unless otherwise defined suitably includes single or fused aromatic or non aromatic iieterocyclic rings comprising up to four hetero atoms in the ring selected from oxygen, nitrogen, and sulphur and optionally substituted with up to three halogen, C16 alkyl, C1 6 alkoxy, halo C1 6 alkyl, hydroxy, amino, carboxy, C16 alkoxycarbonyl, C1 6 alkoxycarbonyl C1 6 alkyl, aryl, oxo, carboxy C1 6 alkyl, carbamoyl C 1 6 alkyl, amino C1 6 alkyl, substituted amino C1 6 alkyl or sulphonyl C1 6 alkyl groups. Suitably the heterocyclic ring comprises from 4 to 7 ring atoms, preferably 5 or 6 atoms.When used herein the term lower indicates that the group contains 1 to 6 carbon atoms.Suitably Y is EMI7.1 wherein Y2 is oxygen, sulphur or CH2 and Z is as hereinbefore defined.Preferred values for Y in the compounds of formula III are S C CH3 2 and S CH2 C CH2Q , ie when the compound of formula III is a derivative of a penicillin or cephalosporin.A particularly preferred value for Y is S C CH3 2 . A further preferred value for Y is S CH2 CZ wherein Z is as hereinbefore defined. The imine of formula III is prepared by treatment with base of a compound of formula IV EMI8.1 wherein R1, R2, Rx and Y are as hereinbefore defined and wherein any reactive groups may be protected.Suitable compounds within formula IV are those of formula V EMI8.2 wherein R1 and Rx are as hereinbefore defined and wherein any reactive groups may be protected and Y3 is EMI8.3 It will also be appreciated that the imine I may be generated in a similar manner to that described above from a compound of partial structure IIA EMI9.1 wherein R1 and R2 are as hereinbefore defined.The imines of formulae I and III are often unstable intermediates and are conveniently reacted in situ without isolation, to form other 3 lactam compounds.In particular, an imine of partial structure I as hereinbefore defined can be converted to a 3 lactam having the partial structure VI EMI9.2 wherein R1 is as hereinbefore defined, by reaction with a nucleophilic derivative of formamide, as described in our copending European Patent Application No.84300338.5Suitable nucleophilic derivatives of formamide includeN silyl, N stannyl and N phosphorylated derivatives. By the term N silyl derivative of formamide is meant the product of reaction of the amino group of formamide with a silylating agent such as a halosilane or a silazane of the formula L3 Si U L2 Si U2, L3 Si NL2 L3 Si NH Si L3 L3 Si NH COL L3 Si NH CO NH Si L3 L NH CO NH Si L3 LC OSi L3 NSiL3 wherein U is a halogen and the various groups L which may be the same or different, each represent hydrogen, alkyl, alkoxy, aryl, or aralkyl. Preferred silylating agents are silyl chlorides, particularly trimethylchlorosilane.The term N stannyl derivative of formamide includes the product of reaction of the amino group of formalnide with a stannylating agent such as a halostannane of formula L3SnU wherein L and U are as defined hereinbefore.The term N phosphorylated derivative of formamide is intended to include compounds wherein the amino group of formamide is substituted with a group of formula P.Rj Rk wherein Rj is an alkyl, haloalkyl, aryl, aralkyl, alkoxy, haloalkoxy, aryloxy, aralkyloxy or dialkylamino group, Rk is the same as Raj or is halogen or Rj and Rk together form a ring.Other suitable nucleophilic derivatives of formamide includeEMI11.1 wherein R and R may be the same or different and each represent a C16 alkyl group or R and R together represent a C24 alkylene di radical.Preferably the nucleophilic derivative of formamide is a N,N bis tri loweralkylsilyl formamide, in particular N,N bis trimethylsilyl formamide.Suitable solvents in which the reaction may be performed include for example, tetrahydrofuran, dimethylformamide, dichloromethane and methylisobutylketone. The reactions are generally carried out under an inert atmosphere and at moderate to low temperatures i.e. in the range 1000C to 300C.The course of the reaction may be followed by conventional methods such as thin layer chromatography and terminated when an optimum quantity of product is present in the reaction mixture. Subsequent to the reaction it may be necessary to regenerate the formamido group from any derivative suitable methods include those known in the art such as, for example, acid or base hydrolysis or treatment with a metal ion such as mercury, silver, thallium, lead or copper.Thus in a further aspect of the invention there is provided a process for the preparation of a compound of partial structure VI EMI12.1 wherein R1 is as hereinbefore defined by treating a compound of partial structure II , EMI12.2 wherein R1 and R2 are as hereinbefore defined with i a non nucleophilic base and subsequently in situ with ii a nucleophilic derivative of formamide.Suitable non nucleophilic bases and nucleophilic derivatives of formamide are described hereinbefore. An example of the above process is the preparation of a compound of formula VII or a salt thereof EMI13.1 wherein R1 and Y are as defined hereinbefore R3 is hydrogen or a readily removable carboxyl protecting group which process comprises treating an intermediate imine of formula III as hereinbefore defined wherein any reactive groups may be protected with a nucleophilic derivative of formamide and thereafter, if necessary, carrying out one or more of the following steps i removing any protecting groups ii converting a group Rx to a group R3 iii converting one group Z into a different group Z iv converting the product into a salt. Those compounds of the formula VII wherein R3 is a readily removable carboxyl protecting group or a non pharmaceutically acceptable salt, are useful as intermediates in the preparation of compounds of the formula VII wherein R3 is a free carboxyl group or a pharmaceutically acceptable salt thereof. The conversion referred to above may be accomplished by procedures per se well known in the art. Also included within the readily removable carboxyl protecting groupsR3 are pharmaceutically acceptable in vivo hydrolysable ester groups. Examples of suitable pharmaceutically acceptable in vivo hydrolysable ester groups include those which break down readily in the human body to leave the parent acid or its salt. Suitable ester groups of this type include those of part formula i , ii and iii EMI14.1 CO2CH2R iii wherein Ra is hydrogen, methyl, or phenyl, Rb is C16 alkyl, C16 alkoxy or phenyl or Ra and Rb together form a 1,2 phenylene group optionally subsituted by one or two methoxy groups Rc represents C1, alkylene optionally substituted with a methyl or ethyl group Rd and Re independently represent C16 alkyl Rf represents C16 alkyl. Examples of suitable in vivo hydrolysable ester groups include for example acyloxyalkyl groups such as acetoxymethyl, pivaloyloxymethyl, a acetoxyethyl and a pivaloyloxyethyl groups alkoxycarbonyloxyalkyl groups such as ethoxycarbonyloxymetilyl and a ethoxycarbonyloxyethyl dialkylaminoalkyl especially di loweralkylamino alkyl groups such as dimethylaminomethyl, dimethylaminoethyl, diethylaminomethyl or diethylaminoethylt lactone groups such as phthalidyl and dimethoxyphthalidyl and esters linked to a second p lactam antibiotic or to a 3 lactamase inhibitor.Suitable readily removable carboxyl protecting groups for the group Co2R3 in formula VII and CO2RX in formula III include salt and ester derivatives of the carboxylic acid. The derivative is preferably one which may readily be cleaved.Suitable ester forming carboxyl protecting groups are those which may be removed under conventional conditions. Such groups for R3 and Rx include benzyl, p methoxybenzyl, benzoylmethyl, p nitrobenzyl, 4 pyridylmethyl, 2,2, 2 trichloroethyl, 2,2,2 tribromoethyl, t butyl, t amyl, allyl, diphenylmethyl, triphenylmethyl, adamantyl, 2 benzyloxyphenyl, 4 methylthiophenyl, tetrahydrofur 2 yl, tetrahydropyran 2 yl, pentachlorophenyl, acetonyl, p toluenesulphonylethyl,methoxymethyl, a silyl, stannyl or phosphorus containing group, an oxide radical of formula N CHRO where RO is aryl or heterocyclyl, or an in vivo hydrolysable ester radical such as defined above. The carboxyl group may be regenerated from any of the above esters by usual methods appropriate to the particular R3 or Rx group, for example, acid and base catalysed hydrolysis, or by enzymically catalysed hydrolysis, or by hydrogenolysis.Suitable pharmaceutically acceptable salts of the carboxy group of the compounds of formulae VII and III include metal salts eg aluminium, alkali metal salts such as sodium or potassium, alkaline earth metal salts such as calcium or magnesium and ammonium or substituted ammonium salts, for example those with lower alkylamines such as triethylamine, hydroxy lower alkylamines such as 2 hydroxyethylamine, bis 2 hydroxyethyl amine or tris 2 hydroxyethyl amine, cycloalkylamines such as dicyclohexylamine, or with procaine, dibenzylamine,N,N dibenzylethylene diamine, l ephenamine,N ethylpiperidine, N benzyl p phenethylamine, dehydroabietylamine, N,N bisdehydro abietylamine, ethylenediamine, or bases of the pyridine type such as pyridine, collidine or quinoline, or other amines which have been used to form salts with known penicillins and cephalosporins. Other suitable salts include the lithium and silver salt.The antibacterial compounds produced by the process of the present invention may be formulated into pharmaceutical compositions according to techniques per se known in the art and administered by conventional routes and dosage rates for example, as disclosed inUS Patent Application No. 401266 and European PatentApplication No. 8230382.1 publication No. 0071395 which are incorporated herein by reference.Compounds of formula VI wherein R1 is as hereinbefore defined serve primarily as valuable intermediates for the preparation of other p lactam compounds. Thus, it will be appreciated that removal of the carboxylic acyl amino protecting group R1 from a compound of partial structure VI will give a lactam of structure VIII EMI17.1 wherein the amino group may be acylated by known techniques to produce lactams having the partial structure IX EMI17.2 wherein R4Co is an acyl group.Suitably, removal of a carboxylic acyl amino protecting group R1 from a compound of structure VII or a salt thereof will afford a p lactam of structure X EMI17.3 wherein R3 and Y are as defined hereinbefore. Methods for preparing compounds of partial structure IX wherein R4 is as hereinbefore defined from p lactams of partial structure VIII are described inEuropean Patent Application No. 82303821.1 PublicationNumber 0 071 395 .A preferred group of compounds that may be produced from 3 lactams of structure X by such methods can be represented by the formula XI or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof EMI18.1 wherein Y is as defined with respect to formula III and R4 is a group such that R4 Co is an acyl group, in particular an acyl group found in antibacterially active penicillins or cephalosporins.Compounds of partial structure II are obtained by reacting a compound of formula XII EMI18.2 wherein R1 is as hereinbefore defined, with base and a source of positive halogen. A suitable source of halogen is tert butyl hypochlorite.Suitable bases include 1,8 diazabicycloE5.4.0 undec 7 ene, 1, 5 diazabicyclo 4. 3.0 non 5 ene, 1,4 diazabicyclo 2.2.2. octane, dimethylaminopyridine or a tri lower alkyl amine. Suitable solvents in which the reaction may be carried out include for example, tetrahydrofuran, dimethylformamide, dichloromethane and methylisobutylketone. The reactions are generally carried out under an inert atmosphere and at moderate to low temperatures i.e. in the range 1000C to 3ooC. Compounds of formula lIA , IV and V can be produced in an analogous manner.Compounds oE EormuLa XII are known in the art and may be prepared by conventional methods from compounds of partial structure XIII .EMI19.1 The following Examples illustrate the process of the invention. Preparation 1Benzyl 613 2,2,2, trichloroethoxycarbonylamino penicillanate Benzyl 6 6y aminopenicillanate toluene 4 sulphonate 120g 0.25 mol was partitioned between ethyl acetate 750cm3 and saturated aqueous sodium bicarbonate 1000cm3 . The phases were separated and the aqueous phase re extracted with ethyl acetate 2 x 250cm3 . The combined extracts were washed with water 500cm3 followed by aqueous sodium chloride 500cm3 . The organic solution was dried over anhydrous magnesium sulphate, filtered and the filtrates cooled to 250C.Pyridine 22cm3 0.28 mol was added followed by 2,2,2 trichloroethyl chloroformate 54g 0.256 mol dropwise over 0.25 hour. The mixture was warmed to ambient temperature during 2 hours and washed sequentially with 1.OM hydrochloric acid 3 x 500cm3 , water 500cm3 , saturated aqueous sodium bicarbonate 3 x 500cm3 , saturated aqueous sodium chloride and dried anhydrous magnesium sulphate . The organic solution was filtered and the filtrates concentrated in vacuo to give an oil. Trituration with hexane 500cm3 gave an off white solid which was recrystallised from 50 ethyl acetate hexane to give the title compound 90.9g 74.6 . The product ran as one component on t.l.c. SiO2 60F254 50 ethyl acetate hexane at an Rf of 0.61 U.V., 254nm . vmax Nujol Mull 3300, 1770, 1740 and 1545 cm l. 6 CDC13 1.42 and 1.62 6H, 2s, 2 CH3 s , 4.45 1H, s, 3 H , 4.72 1H, s, CC13 CH2 , 5.17 2H, s, PhCH20 , 5.58 3H, br m, 5 H, 6 H, CONH , 7.33 5H, s,C6Hs . Example 1Benzyl 6 formamido 6p 2,2,2 trichloroethoxycarbonylaminopenicillanate Benzyl 6R 2,2,2, trichloroethoxyearbonylamino penicillanate 1050mg 2.2mmol was dissolved in dry tetrahydrofuran at 76 under an atmosphere of nitrogen. l,8 DiazabicycloE5.4.0 undec 7 ene D.B.U. 304mg 2mmol was added and the mixture was stirred for 5 minutes at 76 . Next tert butyl hypochlorite 217mg 2mmol was added, and the mixture was stirred for a further 5 minutes at 75 before addition of bis trimethylsilyl formamide 0.42cm3 2mmol the reaction mixture was then warmed to ambient temperature during 2 hours.Ethyl acetate 20cm3 was added and the mixture was washed sequentially with 1 hydrochloric acid 2 x 30cm3 , water 30cm3 , saturated aqueous sodium bicarbonate 2 x 30cm3 and saturated sodiurn chloride 2 x 30cm3 . The organic solution was dried anhydrous magnesium sulphate , filtered, and the filtrate reduced in vacuo to an oil. The oil was dissolved in diethyl ether 10cm3 and the product crystallised on stirring at 50. The material was collected by filtration, washed with diethyl ether at 5 and dried in vacuo to give the title compound 230mg 22 .The material ran as one main component on t.l.c. SiO2 60F254 50 ethyl acetate hexane at an Rf of 0.35 U.V. 254nm . vmax Nujol Mull 3340, 3160, 1795, 1745, 1670, 1530 and 1495 cm l, CDCl3 1.37 and 1.53 6H, 2s, 2 CH3 s , 4.52 1H, s, 3 H , 4.72 2H, s, C13CCH2 , 5.17 2H, s, PhCH2O , 5.66 1H, s, 5 H , 6.75 1H, br 8, D20 exchangeable NH , 7.34 5H, s, C6Hs , 7.70 1H, br s, D20 exchangeable NH CHO and 8.19 1H, s, NHCHO . Preparation 2Benzyl 6B ethoxycarbonylaminopenicillanate The title compound was prepared by a similar procedure to that described in Preparation 1, using ethyl chloroformate 2.5g, 0.023 mole . The product was obtained after removal of the solvent, as a viscous oil 6.7g, 89 . CDC13 l.27 3H,t,J 7Hz,C113CH2 , 1.40 and 1.65 6H,2s,2xCH3 , 4.00 2H,q,J 7Hz,CH3CH2 , 4.35 lH,s,3 R , 4.98 2H,s,PhCH20 , 5.1 5.8 3H,m,5H,6H and CONH , 7.15 5H,s,PhCH20 .Example 2Benzyl 6 ethoxycarbonylamino 6a fornamidopenici11anate Benzyl 66 ethoxycarbonylaminopenicillanate 1.13g 0.003 mole was dissolved in dry tetrahydrofuran 10cm3 and cooled to 650 under an atmosphere of nitrogen. Added D.B.U. 0.45g 0.003 mole and the mixture was stirred for 5 minutes at 650. Added t butylhypochlorite 0.34g 0.0032 mole and stirred for a further 5 minutes at 650. Added bis trimethylsilyl formamide 4.77g 0.025 mole and the reaction mixture warmed to ambient temperature during 2 hours. Ethyl acetate 30cm3 and water 30cm3 were added to the reaction mixture. The phases were separated and the organic phase washed sequentially with 0.1M hydrochloric acid 30 cm3 , 0.1M sodium bicarbonate 30cm3 , water 30cm3 and saturated aqueous sodium chloride 30cm3 . The organic soluton was dried anhydrous magnesium sulphate filtered and the filtrates reduced in vacuo to an oil. The product was purified by column chromatography on silica G60 30g , using ethyl acetate n hexane 1 1 as eluent. Removal of the solvent in vacuo gave the title compound as a pale yellow foam 0.54g 43 . The material ran as one component on t.l.c. silica, 60F 254i ethyl acetate n hexane, 1 1 at an Rf of 0.10 u.v. 254 n.m. . wmax KBr , 3300, 2990, 1780, 1740, 1690, 1510, 1500, 1260cm. G CDC13 , 1.25 3H,m,CH3CH2 , 1.38 and 1.55 6H,2s,2 x CH3 , 4.15 2H,m,CH3CHo 4.54 1H,s,3 H , 5.20 2El,m,PhCE12 , 5.68 1H,s,5 H , 6.30 1H,br.s,D20 exchange,CONH , 7.35 5H,s,PhCH2 , 7.67 1H,br.s,D20 exchange, NHCHO , 8.21 1H,s,NHCHO . Preparation 3 Benzyl 6ss benzyloxycarbonylaminopenicillanate The title compound was prepared by a similar procedure to that described in Preparation 1, using benzyl chloroformate 4.5g 0.025 mole . The product was obtained as a viscous oil 8.7g 100 . 6 CDC13 , 1.35 and 1.50 6H,2s,2 x PhCHv , 5.35 2H,bs,5 H,6 H , 5.6 5.9 1H,bs,CONH , 7.15 10H,bs,2 x PhCH2 . Example 3. Benzyl 6ss benzyloxyearbonylamino 6a fonmamidopenicillanate Benzyl 6ss benzyloxycarbonylaminopenicillanate 1.32g 0.003 mole was dissolved in dry tetrahydrofuran 10cm3 at 650 under an atmosphere of nitrogen. Added D.B.U. 0.45g 0.003 mole and the mixture was stirred for 5 minutes at 650. Added t butylhypochlorite 0.34g 0.003 mole and stirred for a further 5 minutes at 65 . Added bis trimethyl silyl formamide 4.77g 0.025 mole and the reaction mixture warmed to ambient temperature during 2 hours. Ethyl acetate 30cm3 and water 30cm3 were added to the reaction mixture and the phases separated. The organic phase was washed sequentially with 0.1M hydrochloric acid 30cm3 , O.1M hydrochloric acid 30cm3 , 0.1M sodium bicarbonate 30cm3 , water 30cm3 and saturated aqueous sodium chloride 30cm3 . The organic solution was dried anhydrous magnesium sulphate , filtered and the filtrates reduced in vacuo to an oil. The product was purified by column chromatography on silica G60 30g , using ethyl acetate n hexane 1 1 as eluent. Removal of the solvent in vacuo gave the title compound as a pale yellow foam 0.94g, 65 . The material ran as one component on t.l.c. Silica 60F254 ethyl acetate n hexane, 1 1 at an Rf of 0.10 u.v. 254nm . umax KBr , 3350, 2965, 1785, 1740, 1690, 1510, 1450, 1260cm l. 6 CDC13 , 1.40 and 1.52 6H,2s,2 x CH3 , 4.54 1H,s,3 H , 5.0 5.3 4H,m, 2 x PhCH2 , 7.53 1H,bs,D20 exchange, NHCHO , 8.19 lH,s,NHCHO . Preparation 4 4 Nitrobenzyl 6B 2 ,2 ,Z trichloroethoxycarbonylaminopenicillanate The title compound was prepared using a similar procedure to that described in Preparation 1, using 4 nitrobenzyl 6ss aminopenicillanate toluene 4 sulphonic acid salt 13.2g 0.025M and 2,2,2 trichloroethyl chloroformate 3.5cm3 0.025M . The reaction afforded the title compound 11.04g 86 as a crisp white foam 6 CDC13 1.50 and 1.70 6H,2s,geminal dimethyl , 4.50 1H,s,C 3 H , 4.77 2H,s,C13CCH2 , 5.30 2H,s,Ar CH2 , 5.57 2H,m,C 5 H and C 6 H , 7.52 2H,d,JlOHz, aromatic , 8.22 2H,d,J9Hz, aromatic .Example 4 4 Nitrobenzyl 6 alpha formamido 6ss 2 ,2 ,2 trichloroethoxycarbonylaminopenicillanate 4 Nitrobenzyl 6B 2,2y2 trichloroethoxycarbonylaminopenlcillanate l.Og, 0.002M was dissolved in dry tetrahydrofuran 5cm3 at 650 under an atmosphere of nitrogen. Added DBU 0.3cm3, 0.002M and the mixture was stirred for 5 minutes at 650. Added t butylhypochlorite 0.22cm3, 0.002M and stirred for a further 5 minutes at 65 . Added bis trimethylsilyl formamide 3cm3, 0.014M and the mixture warmed to ambient temperature during 2 hours.Added ethyl acetate 30cm3 and water 30cm3 , separated, and the organic layer washed sequentially with 0.1M hydrochloric acid 30cm3 , O.1M sodium carbonate 30cm3 and saturated sodium chloride 30cm3 . The organic solution was dried anhydrous magnesium sulphate , filtered, and the filtrates evaporated in vacuo to an oil. The oil was chromatographed on silica gel, eluting with ethyl acetate hexane 1 1 .Evaporation of the appropriate fractions afforded the title compound 200mg, 18 as a pale yellow foam vmax CHC13 1260, 1315, 1400, 1500, 1640, 1680, 1760, 1840, 1900, 1940, 3300cm l d CDC13 , 1.35 and 1.50 6H,2s,geminal dimethyl , 4.52 lH,s,C 3 H , 4.68 2H,s,C13CH2 , 5.19 and 5.27, B lH,J13.4Hz and A 1H,J13,1Hz ABq,Ar CH2 ,5.68 1H,s,C 5 H , 7.03 1H,s, NHCHO , 7.51 2H,d,J8.7Hz, aromatic 8.15 4H,m,OCONH, NTHCH0, aromatic . Preparation 5.4 Nitrobenzyl 6ss 4 nitrobenzyloxycarbonylamino penicillanate The title compound was prepared from 4 nitrobenzyl 6 aminopenicillanate, 4 toluene sulphonate 5.23g 0.01mole and 4 nitrobenzyl chloroformate 2.16g 0.01mole , by a procedure similar to that described inPreparation 1. The product was obtained as an off white foam 5.2g 98 . d CDC13 , 1.46 and 1.66 6H,2s,2 x CH3 , 4.48 1H,s,3 H , 5.19 and 5.27 411,2s,2 x N02PhCH2 , 5.36 5.93 and 5.50 3H,s bm,6 H,5 H, CONH , 7.267.65 and 7.96 8.29 8H,2bm,2 x NO2PhCH2 . The product ran as one main component on t.l.c. at an Rf of 0.31 with small impurities at 0.44 and 0.56. SiO2 60F254 50 ethyl acetate n hexane u.v. 254nm . The material was used without further purification.Example 5.4 Nitrobenzyl 6 alpha formamido 6ss 4 nitrobenzyloxycarbonylamino penicillanate 4 Nitrobenzyl 6ss 4 nitrobenzyloxyearbonylamino penicillanate 2.65g 0.005mole was dissolved in dry tetrahydrofuran 50cm3 and cooled to 650 under an atmosphere of nitrogen. Added DBU 0.75cm3 and the mixture was stirred at 650 for 5 minutes. Added t butylhypochlorite 0.585cm3 and stirring was continued for a further 5 minutes at 650. Excess of bis trimethylsilyl formamide 8.0cm3 was added and the reaction mixture warmed to ambient temperature during 2.0 hours.The mixture was partitioned between ethyl acetate 50cm3 and water 50cm3 . The organic phase was washed sequentially with 1M hydrochloric acid 50cm3 , 0.5M sodium bicarbonate 50cm3 and saturated aqueous sodium chloride 50cm3 . The solution was dried anhydrous magnesium sulphate and concentrated in vacuo to a yellow foam. The title compound was obtained after chromatography on silica G60 30g , eluting with ethyl acetate n hexane 1 1 followed by ethyl acetate, as a pale yellow solid 1.06g 37 melting at 92 96 . v max KBr , 3320, 2980, 1783, 1745, 1695, 1610, 1525, 1350cm 1. t CDC13 42 and l.56 6H,2s, 2 x CH3 , 4.58 1H,s,3 H , 5.26 4H,m,2 x N02PhCE2 5.67 1H,s,5 H , 6.48 6.62 1R,bd,D2O exchange, cho COWNIt, 7.53 5H,m,AROM. NHCHO , 8.23 5H,m,AROM. NECEO . Preparation 6Methyl 6B benzyloxycarbonylaminopenicillanate 6 Aminopenicillanic acid 21.6g O.lmole was slurried in water 150cm3 and the pH adjusted to 8.5 by addition of 2M sodium hydroxide.Solution cooled to 50 in an ice salt bath. Added benzyl chloroformate 18.7g 0.11 mole dropwise, maintaining the pH at 8.5 by concurrent addition of 1M sodium bicarbonate. When the pH was stable the solution was warmed to ambient temperature and stirred for 1 hour. The solution was washed with diethyl ether 2 x 200cm3 , covered with ethyl acetate 250cm3 and acidified to pH 2.0 with 2M hydrochloric acid. Phases separated.The aqueous phase was further extracted with ethyl acetate 200cm3 and the combined organic phases washed with saturated aqueous sodium chloride 2 x 150cm3 , dried anhdyrous magnesium sulphate and the solvent removed in vacuo to give 68 benzyloxycarbonplaminopenicillanic acid 35.9g 100 as a crisp, white foam 6 CDC13 , 1.56 and 1.61 6H,2s,2 x CH3 , 4.38 1H,s,3 H , 5.08 2H,s,Ph H2 , 5.29 5.97 3H,bm,5 H,6 H,CONH , 7.24 5H,s,PhCH2 , 10.11 1H,bs,D20 exchange,CO2H . The major impurity appeared to be ethyl acetate. The material was used for the next reaction without further purification. 6ss Benzyloxycarbonylaminopenicillanic acid 3.5g 0.01 mole was dissolved in dimethylformamide 20cm3 , the solution stirred at ambient temperature, and treated with triethylamine 1.52g 0.015 mole followed by iodomethane 2.28g 0.015 mole . The reaction was stirred 1.5 hours at ambient temperature, then diluted with ethyl acetate 150cm3 , and water 150cm3 . The organic extract was washed with water 2 x 50cm3 , O.5M sodium bicarbonate 50cm3 , water 50cm3 , saturated aqueous sodium chloride 25cm3 and dried anhydrous magnesium sulphate . After filtration, the filtrate was reduced in vacuo to give methyl 6ss benzyloxycarbonylaminopenicillanate 2.0g 55 as a crisp, yellow brown foam. 6 CDC13 1.45 and 1.63 6H,2s,2 x CH3 , 3.68 3H,s,C02CH3 , 4.39 1H,s,3 H , 5. 05 2H,s,PhCH2 , 5.3 5.9 3H,bm,5 H,6 H,CONH , 7.24 5H,s,PhCH2 . Example 6Methyl 66 benzyloxycarbonylamino 6a formamidopenicillanate methyl 6ss benzyloxycarbonylaminopenicillanate 1.09g, 0.003 mole was dissolved in dry tetrahydrofuran 10cm3 and cooled to 65 under an atmosphere of nitrogen. Added D.B.U. 0.45g 0.003 mole and the mixture was stirred for 5 minutes at 650. Added t butylhypochlorite 0.34g 0.0032 moles and stirred for a further 5 minutes at 650.Added bis trimethylsilyl formamide 4.77g 0.025 moles and the reaction mixture warmed to ambient temperature during 2 hours. Ethyl acetate 30cm3 and water 30cm3 were added to the reaction mixture.The phases were separated and the organic phase washed sequentially with 0.1M hydrochloric acid 30cm3 , 0.1M sodium bicarbonate 30cm3 water 30cm3 , and saturated aqueous sodium chloride 30cm3 . The organic soluton was dried anhydrous magnesium sulphate , filtered, and the filtrates reduced in vacuo to an oil. The product was purified by column chromatography on silica G60 30g using ethyl acetate n hexane l l as eluent. Removal of the solvent in vacuo gave the title compound as a pale yellow foam 0.28g, 23 . The material ran as one component on t.l.c. silica, 60F254 ethyl acetate n hexane 1 1 at an Rf of 0.10 u.v. 254nm . max KBr 3310, 2970, 1785, 1690 1740 b , 1510, 1500, 1265, 1220. 1.h5 13 1.45 and 1.53 6H,2s,2 x CH3 , 3.76 3H,s,CO2CH3 , 4.51 1H,s,3 H , 5 12 2HsnXPhCH2 , 5.67 1H,s,5 H , 6.42 1H,bd,CONH , 7.33 5H,s,PhCH2 7.72 1H,bs,D20 exchange, NHCHO , 8.17 lH,s,NHCHO . PreE C ien 7 t Butvl 7ss 2,2,2 trichloroethoxycarbonylamino cephalosporanate The title compound was prepared by a similar procedure to that described in Preparation 1 from t butyl 7B aminocephalosporanate 5g, 0.015 moles . The product was obtained, after evaporation of the solvent, as a yellow brown foam 8g, 100 . The product ran as one component on t.l.c. silica 60F254 ethyl acetate n hexane 1 1 at an Rf of 0.70 u.v. 254n.m. . CDcl3 1.53 9H,s, CH3 3C , 2.05 3H,s,CH2OCOCH3 , 3.45 2H,bs,CH2 at 2 C 4.45 5.1 5H,m,Cl3CCH2O, CH20COCH3, 6 H , 5.4 5.75 1H,m,7 H , 6.55 1H,bd,CONH . Example 7 t Butyl 7 alpha formamido 7ss 2,2,2 trichloroethoxycarbonylamino cephalosporanate t Butyl 7ss 2,2,2 trichloroethoxycarbonylamino cephalosporanate lOg 0.02 moles was dissolved in dry tetrahydrofuran 100cm3 and cooled to 600 under an atmosphere of nitrogen. Added D.B.U. 3.05g 0.02 moles and the mixture was stirred for 5 minutes at 600. Added t butyl hypochlorite 2.04g 0.019 moles and stirred for a further 5 minutes at 600. added bis trimethylsilyl formamide 3.8g 0.02 moles and the reaction mixture warmed to ambient temperature during 4 hours.ethyl acetate 100cm3 and water 100cm3 were added to the reaction mixture. The phases were separated and the organic phase washed sequentially with 0.5M hydrochloric acid 25cm3 , water 25cm3 , 0.25N sodium bicarbonate 25cm3 , water 25cm3 . and saturated aqueous sodium chloride 25cm3 . The organic solution was dried anhydrous magnesium sulphate , filtered, and the filtrates reduced in vacuo to an oil. The product was purified by column chromatogrphy on silica C60 log using ethyl acetate n hexane 1 1 as eluent. Removal of the solvent in vacuo gave an oil which was further purified by column chromatography C60 35g using chloroformmethanol acetic acid 95 5 1 as eluent. Removal of the solvent in vacuo gave the title compound as a pale brown foam 400mg 3.7 . The material ran as one component on t.l.c. silica 60F254 ethyl acetate n hexane 1 1 at an Rf of 0.15 u.v. 254nm .vmax CH2C12 3380, 1790, 1735 and 1700cm l. CDC13 1.50 9H,m, CH3 3 , 2.09 3H,s,CH2OCOCH3 , 3.2 3.65 2H,m,CH2 at 2 C , 4.55 5.2 5H,m,C13CH20, CH20COCII3, 6 H , 6.67 1H,s,D20 exch., CONH , 7.70 1H,bs,D20 exch.NHCHO , 8.26 1H,s,NHCHO . Example 8Benzyl 63 benzyloxycarbonylamino 6a formamidopenicillanate Benzyl 66 benzyloxyearbonylaminopenicillanate 0. 82g, 0.00186M from Preparation 3 was dissolved in dry tetrahydrofuran 8cm3 at 650 under an atmosphere of nitrogen. Added 1,5 diazabicyclo 4.3.0 non 5 ene 0.27g 0.00218 M and the mixture was stirred for 5 minutes at 650. Added t butylhypochlorite 0.24g, 0.00212M and stirred for a further 5 minutes at 650. Added bis trimethylsilyl ormamide 2.5g, 0.013M and the reaction mixture warmed to ambient temperature during 2 hours. Ethyl acetate 25cm3 and water 25cm3 were added to the reaction mixture and the phases separated. The organic phase was washed sequentially with 0.1M hydrochloric acid 25cm3 , O.lM sodium bicarbonate 25cm3 , water 25cm3 and saturated aqueous sodium chloride 25cm3 .. The organic solution was dried anhydrous magnesium sulphate , filtered and the filtrates reduced in vacuo to an oil. The product was purified by column chromatography on silica G60 lOg , using ethyl acetaten hexane 1 1 as eluent. Removal of the solvent in vacuo gave the title compound as a pale yellow oil. 0.085g, 9.5 . The material ran as one component on t.l.c. silica 60F254 ethyl acetate n hexane, 1 1 at an Rf of 0.10 u.v. 254nm . The spectral data were identical in all respects to that obtained in example 3.